Top

Medication-Induced Hyperglycemia and Diabetes Mellitus: A Review of Current Literature and Practical Management Strategies

Journals by subject

Editor's Choice | Journals

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest Journal Issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Stay up to date with medical journals in your specialty

Already registered? Log in here

Looking for something specific?

Find articles from over 500 clinical journals from Springer with the search function.

Latest issues in Internal Medicine

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Cardiology

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Diabetes & Endocrinology

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Neurology

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Oncology

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Pediatrics

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Respiratory Medicine

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

About journals on Springer Medicine

The range of medical journals on Springer Medicine is extremely diverse. It includes the current editions and archives of around 500 English-language journals from almost all medical disciplines published by Springer.

The specialist literature is usually available both online in full text and as a PDF for download. The online view is optimized in such a way that the specialist texts can be read comfortably on all screen sizes, from desktops to tablets to smartphones. We also include features to support your use of the journals for your research, such as bookmark setting.

Whether you’re interested in internal medicine, surgery, general medicine, gynecology, orthopedics, neurology, or pediatrics, there are excellent journals in almost every subject area, such as the BMC Series, Diabetologia, Breast Cancer Research, Current Obesity Reports, CNS Drugs and many others, all of which are an integral part of the everyday life of doctors across Europe.

The breadth of content from this suite of journals allows the Springer Medicine team to collect and deliver broad-ranging content across the full spectrum of medical knowledge, with a special focus on topics highlighted by these leading journals and their editorial boards and specialist authors. This guarantees a high quality of content and ensures that our readers are offered the most relevant topics in their respective specialist area.

Our experienced clinical content managers constantly monitor the needs of medical professionals to provide up-to-date reports from international congresses, expert interviews, and a range of digestible content on emerging topics in the field of medicine.

Diabetes Therapy

Published in:

Open Access 31-07-2024 | Hyperglycemia | Review

Medication-Induced Hyperglycemia and Diabetes Mellitus: A Review of Current Literature and Practical Management Strategies

Authors: Akshay B. Jain, Valerie Lai

Published in: Diabetes Therapy | Issue 9/2024

Abstract

With the increasing global incidence of diabetes mellitus, physicians may encounter more patients with acute and chronic complications of medication-induced hyperglycemia and diabetes. Moreover, medication-induced diabetes may be an important contributing factor to the high rates of diabetes, and recognizing its impact and risk is a critical step in curtailing its effect on the global population. It has long been recognized that multiple classes of medications are associated with hyperglycemia through various mechanisms, and the ability to foresee this and implement adequate management strategies are important. Moreover, different antihyperglycemic medications are better suited to combat the hyperglycemia encountered with different classes of medications, so it is critical that physicians can recognize which agents should be used, and which medications to avoid in certain types of medication-induced hyperglycemia. In this review, we will discuss the evidence behind the main classes of medications that cause hyperglycemia, their mechanism of action, specific agents that are associated with worsened glycemic control, and, most importantly, management strategies that are tailored to each specific class.

Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. https://doi.org/10.1016/j.diabres.2021.109119. Erratum in: Diabetes Res Clin Pract. 2023;204:110945. https://doi.org/10.1016/j.diabres.2023.110945.

Fathallah N, Slim R, Larif S, Hmouda H, Ben SC. Drug-induced hyperglycaemia and diabetes. Drug Saf. 2015;38(12):1153–68. https://doi.org/10.1007/s40264-015-0339-z.CrossRefPubMed

Jain V, Patel RK, Kapadia Z, Galiveeti S, Banerji M, Hope L. Drugs and hyperglycemia: a practical guide. Maturitas. 2017;104:80–3. https://doi.org/10.1016/j.maturitas.2017.08.006.CrossRefPubMed

LaPreze J, Robinson A. Detecting and managing drug-induced diabetes. US Pharmacist. 2021;46(11):18–30.

Liu XX, Zhu XM, Miao Q, Ye HY, Zhang ZY, Li YM. Hyperglycemia induced by glucocorticoids in nondiabetic patients: a meta-analysis. Ann Nutr Metab. 2014;65(4):324–32. https://doi.org/10.1159/000365892.CrossRefPubMed

Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care. 2006;29(12):2728–9. https://doi.org/10.2337/dc06-1499.CrossRefPubMed

Donihi AC, Raval D, Saul M, Korytkowski MT, DeVita MA. Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients. Endocr Pract. 2006;12(4):358–62. https://doi.org/10.4158/EP.12.4.358.CrossRefPubMed

Li JX, Cummins CL. Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nat Rev Endocrinol. 2022;18(9):540–57. https://doi.org/10.1038/s41574-022-00683-6.CrossRefPubMedPubMedCentral

Schakman O, Kalista S, Barbé C, Loumaye A, Thissen JP. Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol. 2013;45(10):2163–72. https://doi.org/10.1016/j.biocel.2013.05.036.CrossRefPubMed

10.

Xu C, He J, Jiang H, et al. Direct effect of glucocorticoids on lipolysis in adipocytes. Mol Endocrinol. 2009;23(8):1161–70. https://doi.org/10.1210/me.2008-0464.CrossRefPubMedPubMedCentral

11.

Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Lond). 1999;96(5):513–23. https://doi.org/10.1042/cs0960513.CrossRefPubMed

12.

Weinstein SP, Wilson CM, Pritsker A, Cushman SW. Dexamethasone inhibits insulin-stimulated recruitment of GLUT4 to the cell surface in rat skeletal muscle. Metabolism. 1998;47(1):3–6. https://doi.org/10.1016/s0026-0495(98)90184-6.CrossRefPubMed

13.

Shah P, Kalra S, Yadav Y, et al. Management of glucocorticoid-induced hyperglycemia. Diabetes Metab Syndr Obes. 2022;23(15):1577–88. https://doi.org/10.2147/DMSO.S330253.CrossRef

14.

Kulkarni S, Durham H, Glover L, et al. Metabolic adverse events associated with systemic corticosteroid therapy-a systematic review and meta-analysis. BMJ Open. 2022;12(12): e061476. https://doi.org/10.1136/bmjopen-2022-061476.CrossRefPubMedPubMedCentral

15.

Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123(11):1001–6. https://doi.org/10.1016/j.amjmed.2010.06.019.CrossRefPubMed

16.

Choudhry MN, Malik RA, Charalambous CP. Blood glucose levels following intra-articular steroid injections in patients with diabetes: a systematic review. JBJS Rev. 2016;4(3):e5. https://doi.org/10.2106/JBJS.RVW.O.00029.CrossRefPubMed

17.

Andersen YMF, Egeberg A, Ban L, et al. Association between topical corticosteroid use and type 2 diabetes in two European population-based adult cohorts. Diabetes Care. 2019;42(6):1095–103. https://doi.org/10.2337/dc18-2158.CrossRefPubMed

18.

Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, González-González JG, Tamez-Peña AL. Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: a narrative review. World J Diabetes. 2015;6(8):1073–81. https://doi.org/10.4239/wjd.v6.i8.1073.CrossRefPubMedPubMedCentral

19.

Aberer F, Hochfellner DA, Sourij H, Mader JK. A practical guide for the management of steroid induced hyperglycaemia in the hospital. J Clin Med. 2021;10(10):2154. https://doi.org/10.3390/jcm10102154.CrossRefPubMedPubMedCentral

20.

Yata Y, Hosojima M, Kabasawa H, et al. The assessment of the efficacy of dipeptidyl peptidase-4 inhibitors in patients with glucocorticoid-induced diabetes by continuous glucose monitoring. Intern Med. 2017;56(19):2555–62. https://doi.org/10.2169/internalmedicine.8296-16.CrossRefPubMedPubMedCentral

21.

Gerards MC, Venema GE, Patberg KW, et al. Dapagliflozin for prednisone-induced hyperglycaemia in acute exacerbation of chronic obstructive pulmonary disease. Diabetes Obes Metab. 2018;20(5):1306–1310. https://doi.org/10.1111/dom.13209.

22.

Appendix 8 - Sick-day medication list. Canadian J Diabetes. 2018;42(1):S316. https://doi.org/10.1016/j.jcjd.2017.10.045.

23.

James J, Roberts A, Dhatariya K. Joint British Diabetes Societies for inpatient Care: management of hyperglycemia and steroid (glucocorticoid) therapy. Jan 2023. https://abcd.care/sites/default/files/site_uploads/JBDS_Guidelines_Current/JBDS_08_Management_of_Hyperglycaemia_and_Steroid_(Glucocorticoid)_Therapy_with_QR_code_January_2023.pdf. Accessed 30 June 2024.

24.

Vancampfort D, Wampers M, Mitchell AJ, et al. A meta-analysis of cardio-metabolic abnormalities in drug naive, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry. 2013;12(3):240–50.CrossRefPubMedPubMedCentral

25.

Kessing LV, Thomsen AF, Mogensen UB, Andersen PK. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry. 2010;197(4):266–71. https://doi.org/10.1192/bjp.bp.109.076935.CrossRefPubMed

26.

Bobo WV, Cooper WO, Stein CM, et al. Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiat. 2013;70(10):1067–75. https://doi.org/10.1001/jamapsychiatry.2013.2053.CrossRef

27.

Deng C, Weston-Green K, Huang XF. The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain? Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(1):1–4. https://doi.org/10.1016/j.pnpbp.2009.11.009.CrossRefPubMed

28.

Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry. 2001;62(Suppl 27):15–26; discussion 40–1.

29.

Chen J, Huang XF, Shao R, Chen C, Deng C. Molecular mechanisms of antipsychotic drug-induced diabetes. Front Neurosci. 2017;21(11):643. https://doi.org/10.3389/fnins.2017.00643.CrossRef

30.

Engl J, Laimer M, Niederwanger A, et al. Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells. Mol Psychiatry. 2005;10(12):1089–96. https://doi.org/10.1038/sj.mp.4001729.CrossRefPubMed

31.

Han M, Deng C, Burne TH, Newell KA, Huang XF. Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression. Psychoneuroendocrinology. 2008;33(5):569–80. https://doi.org/10.1016/j.psyneuen.2008.01.018.CrossRefPubMed

32.

Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008;13(1):27–35. https://doi.org/10.1038/sj.mp.4002066.CrossRefPubMed

33.

Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet. 2005;20(5):368–78. https://doi.org/10.2133/dmpk.20.368.CrossRefPubMed

34.

Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010;25(Suppl 2):S12-21. https://doi.org/10.1016/S0924-9338(10)71701-6.CrossRefPubMed

35.

Ozasa R, Okada T, Nadanaka S, et al. The antipsychotic olanzapine induces apoptosis in insulin-secreting pancreatic β cells by blocking PERK-mediated translational attenuation. Cell Struct Funct. 2013;38(2):183–95. https://doi.org/10.1247/csf.13012. Erratum in: Cell Struct Funct. 2013;38(2):227. Erratum in: Cell Struct Funct. 2014;39(1):21.

36.

Best L, Yates AP, Reynolds GP. Actions of antipsychotic drugs on pancreatic beta-cell function: contrasting effects of clozapine and haloperidol. J Psychopharmacol. 2005;19(6):597–601. https://doi.org/10.1177/0269881105056641.CrossRefPubMed

37.

De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8(2):114–26. https://doi.org/10.1038/nrendo.2011.156.CrossRefPubMed

38.

Taylor DM, McAskill R. Atypical antipsychotics and weight gain–a systematic review. Acta Psychiatr Scand. 2000;101(6):416–32. https://doi.org/10.1034/j.1600-0447.2000.101006416.x.CrossRefPubMed

39.

Campforts B, Drukker M, Crins J, van Amelsvoort T, Bak M. Association between antipsychotic medication and clinically relevant weight change: meta-analysis. BJPsych Open. 2023;9(1):e18. https://doi.org/10.1192/bjo.2022.619.CrossRefPubMedPubMedCentral

40.

DeJongh BM. Clinical pearls for the monitoring and treatment of antipsychotic induced metabolic syndrome. Ment Health Clin. 2021;11(6):311–9. https://doi.org/10.9740/mhc.2021.11.311.CrossRefPubMedPubMedCentral

41.

Stogios N, Hahn MK, Lunsky Y, Desarkar P, Agarwal SM. Metformin for the treatment of antipsychotic-induced metabolic disturbances in people with intellectual and developmental disabilities. J Psychiatry Neurosci. 2023;48(2):E99–101. https://doi.org/10.1503/jpn.220200.CrossRefPubMedPubMedCentral

42.

Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiat. 2017;74(7):719–28. https://doi.org/10.1001/jamapsychiatry.2017.1220.CrossRef

43.

Prasad F, De R, Korann V, et al. Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series. Ther Adv Psychopharmacol. 2023;13:20451253231165169. https://doi.org/10.1177/20451253231165169. Erratum in: Ther Adv Psychopharmacol. 2024;14:20451253241258536. https://doi.org/10.1177/20451253241258536.

44.

Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis risk in communities study. N Engl J Med. 2000;342(13):905–12. https://doi.org/10.1056/NEJM200003303421301.CrossRefPubMed

45.

Kostis JB, Wilson AC, Freudenberger RS, et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005;95(1):29–35. https://doi.org/10.1016/j.amjcard.2004.08.059.CrossRefPubMed

46.

Helgeland A, Leren P, Foss OP, Hjermann I, Holme I, Lund-Larsen PG. Serum glucose levels during long-term observation of treated and untreated men with mild hypertension. The Oslo study. Am J Med. 1984;76(5):802–5. https://doi.org/10.1016/0002-9343(84)90990-2.CrossRefPubMed

47.

Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ. 1989;298(6681):1152–7. https://doi.org/10.1136/bmj.298.6681.1152.CrossRefPubMedPubMedCentral

48.

Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol. 2007;100(8):1254–62. https://doi.org/10.1016/j.amjcard.2007.05.057.CrossRefPubMed

49.

Rizos CV, Elisaf MS. Antihypertensive drugs and glucose metabolism. World J Cardiol. 2014;6(7):517–30. https://doi.org/10.4330/wjc.v6.i7.517.CrossRefPubMedPubMedCentral

50.

Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. Hypothesis: beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension. 2001;37(2):250–4. https://doi.org/10.1161/01.hyp.37.2.250.CrossRefPubMed

51.

Lithell H, Pollare T, Vessby B. Metabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patients. Blood Press. 1992;1(2):92–101. https://doi.org/10.3109/08037059209077499.CrossRefPubMed

52.

Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens. 1996;14(4):489–94. Erratum in: J Hypertens. 1996;14(11):1382.

53.

Bell DS. Use of beta blockers in the patient with diabetes. Endocrinologist. 2003;13(2):116–23. https://doi.org/10.1097/01.ten.0000076214.95014.05.CrossRef

54.

Teuscher AU, Weidmann PU. Requirements for antihypertensive therapy in diabetic patients: metabolic aspects. J Hypertens Suppl. 1997;15(2):S67-75. https://doi.org/10.1097/00004872-199715022-00006.CrossRefPubMed

55.

Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369(9557):201–7. https://doi.org/10.1016/S0140-6736(07)60108-1. Erratum in: Lancet. 2007;369(9572):1518.

56.

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–97. https://doi.org/10.1001/jama.288.23.2981. Erratum in: JAMA. 2003;289(2):178. Erratum in: JAMA. 2004;291(18):2196.

57.

Zhang X, Zhao Q. Association of thiazide-type diuretics with glycemic changes in hypertensive patients: a systematic review and meta-analysis of randomized controlled clinical trials. J Clin Hypertens (Greenwich). 2016;18(4):342–51. https://doi.org/10.1111/jch.12679.CrossRefPubMed

58.

Shafi T, Appel LJ, Miller ER 3rd, Klag MJ, Parekh RS. Changes in serum potassium mediate thiazide-induced diabetes. Hypertension. 2008;52(6):1022–9. https://doi.org/10.1161/HYPERTENSIONAHA.108.119438. Erratum in: Hypertension. 2009;53(2):e19.

59.

Eriksson JW, Jansson PA, Carlberg B, et al. Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) Study. Hypertension. 2008;52(6):1030–7. https://doi.org/10.1161/HYPERTENSIONAHA.108.119404.CrossRefPubMed

60.

Cooper-DeHoff RM, Wen S, Beitelshees AL, et al. Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension. 2010;55(1):61–8. https://doi.org/10.1161/HYPERTENSIONAHA.109.139592.CrossRefPubMed

61.

Laakso M, Kuusisto J. Diabetes secondary to treatment with statins. Curr Diab Rep. 2017;17(2):10. https://doi.org/10.1007/s11892-017-0837-8.CrossRefPubMed

62.

Navarese EP, Buffon A, Andreotti F, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol. 2013;111(8):1123–30. https://doi.org/10.1016/j.amjcard.2012.12.037.CrossRefPubMed

63.

Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207. https://doi.org/10.1056/NEJMoa0807646.CrossRefPubMed

64.

Beckett RD, Schepers SM, Gordon SK. Risk of new-onset diabetes associated with statin use. SAGE Open Med. 2015;30(3):2050312115605518. https://doi.org/10.1177/2050312115605518.CrossRef

65.

Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556–64. https://doi.org/10.1001/jama.2011.860.CrossRefPubMed

66.

Sampson UK, Linton MF, Fazio S. Are statins diabetogenic? Curr Opin Cardiol. 2011;26(4):342–7. https://doi.org/10.1097/HCO.0b013e3283470359.CrossRefPubMedPubMedCentral

67.

Mitchell P, Marette A. Statin-induced insulin resistance through inflammasome activation: sailing between Scylla and Charybdis. Diabetes. 2014;63(11):3569–71. https://doi.org/10.2337/db14-1059.CrossRefPubMed

68.

Sugiyama T, Tsugawa Y, Tseng CH, Kobayashi Y, Shapiro MF. Different time trends of caloric and fat intake between statin users and nonusers among US adults: gluttony in the time of statins? JAMA Intern Med. 2014;174(7):1038–45. https://doi.org/10.1001/jamainternmed.2014.1927.CrossRefPubMedPubMedCentral

69.

Cholesterol Treatment Trialists’ (CTT) Collaboration. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. Lancet Diabetes Endocrinol. 2024;12(5):306–319. https://doi.org/10.1016/S2213-8587(24)00040-8.

70.

Hong SJ, Lee YJ, Lee SJ, et al. Treat-to-target or high-intensity statin in patients with coronary artery disease: a randomized clinical trial. JAMA. 2023;329(13):1078–87. https://doi.org/10.1001/jama.2023.2487.CrossRefPubMedPubMedCentral

71.

Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013;346:f2610. https://doi.org/10.1136/bmj.f2610. Erratum in: BMJ. 2013;347:f4356.

72.

Yamakawa T, Takano T, Tanaka S, Kadonosono K, Terauchi Y. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb. 2008;15(5):269–75. https://doi.org/10.5551/jat.e562.CrossRefPubMed

73.

Goldie C, Taylor AJ, Nguyen P, McCoy C, Zhao XQ, Preiss D. Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials. Heart. 2016;102(3):198–203. https://doi.org/10.1136/heartjnl-2015-308055.CrossRefPubMed

74.

Park SJ, Park YJ, Chang J, et al. Association between antibiotics use and diabetes incidence in a nationally representative retrospective cohort among Koreans. Sci Rep. 2021;11(1):21681. https://doi.org/10.1038/s41598-021-01125-5.CrossRefPubMedPubMedCentral

75.

Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med. 2006;354(13):1352–61. https://doi.org/10.1056/NEJMoa055191.CrossRefPubMed

76.

Rehman A, Setter SM, Vue MH. Drug-induced glucose alterations. Part 2: drug-induced hyperglycemia. Diabetes Spectr. 2011;24(4):234–8.CrossRef

77.

Mikkelsen KH, Knop FK, Frost M, Hallas J, Pottegård A. Use of antibiotics and risk of type 2 diabetes: a population-based case-control study. J Clin Endocrinol Metab. 2015;100(10):3633–40. https://doi.org/10.1210/jc.2015-2696.CrossRefPubMedPubMedCentral

78.

Ye M, Robson PJ, Eurich DT, Vena JE, Xu JY, Johnson JA. Systemic use of antibiotics and risk of diabetes in adults: a nested case-control study of Alberta’s Tomorrow Project. Diabetes Obes Metab. 2018;20(4):849–57. https://doi.org/10.1111/dom.13163.CrossRefPubMed

79.

Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med. 2000;160(13):2050–6. https://doi.org/10.1001/archinte.160.13.2050.CrossRefPubMed

80.

Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov. 2003;2(10):812–22. https://doi.org/10.1038/nrd1201.CrossRefPubMed

81.

Koster JC, Remedi MS, Qiu H, Nichols CG, Hruz PW. HIV protease inhibitors acutely impair glucose-stimulated insulin release. Diabetes. 2003;52(7):1695–700. https://doi.org/10.2337/diabetes.52.7.1695.CrossRefPubMed

82.

Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998;351(9119):1881–3. https://doi.org/10.1016/S0140-6736(98)03391-1.CrossRefPubMed

83.

Kaufman MB, Simionatto C. A review of protease inhibitor-induced hyperglycemia. Pharmacotherapy. 1999;19(1):114–7. https://doi.org/10.1592/phco.19.1.114.30514.CrossRefPubMed

84.

Brown TT, Glesby MJ. Management of the metabolic effects of HIV and HIV drugs. Nat Rev Endocrinol. 2011;8(1):11–21. https://doi.org/10.1038/nrendo.2011.151.CrossRefPubMedPubMedCentral

85.

Lew S, Chamberlain RS. Risk of metabolic complications in patients with solid tumors treated with mTOR inhibitors: meta-analysis. Anticancer Res. 2016;36(4):1711–8.PubMed

86.

Vergès B, Cariou B. mTOR inhibitors and diabetes. Diabetes Res Clin Pract. 2015;110(2):101–8. https://doi.org/10.1016/j.diabres.2015.09.014.CrossRefPubMed

87.

Yao JC, Shah MH, Ito T, et al. Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514–23. https://doi.org/10.1056/NEJMoa1009290.CrossRefPubMedPubMedCentral

88.

Hobday TJ, Qin R, Reidy-Lagunes D, et al. Multicenter phase II trial of temsirolimus and bevacizumab in pancreatic neuroendocrine tumors. J Clin Oncol. 2015;33(14):1551–6. https://doi.org/10.1200/JCO.2014.56.2082.CrossRefPubMed

89.

Kleinert M, Sylow L, Fazakerley DJ, et al. Acute mTOR inhibition induces insulin resistance and alters substrate utilization in vivo. Mol Metab. 2014;3(6):630–41. https://doi.org/10.1016/j.molmet.2014.06.004.CrossRefPubMedPubMedCentral

90.

Fraenkel M, Ketzinel-Gilad M, Ariav Y, Pappo O, et al. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes. 2008;57(4):945–57. https://doi.org/10.2337/db07-0922.CrossRefPubMed

91.

Ariaans G, Jalving M, Vries EG, Jong S. Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells. BMC Cancer. 2017;17(1):232. https://doi.org/10.1186/s12885-017-3230-8.CrossRefPubMedPubMedCentral

92.

Busaidy NL, Farooki A, Dowlati A, et al. Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol. 2012;30(23):2919–28. https://doi.org/10.1200/JCO.2011.39.7356.CrossRefPubMedPubMedCentral

93.

Vergès B. mTOR and cardiovascular diseases: diabetes mellitus. Transplantation. 2018;102(2S Suppl 1):S47–S49. https://doi.org/10.1097/TP.0000000000001722.

94.

Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251-9. https://doi.org/10.1056/NEJMoa0912614.

95.

Goldman JW, Mendenhall MA, Rettinger SR. Hyperglycemia associated with targeted oncologic treatment: mechanisms and management. Oncologist. 2016;21(11):1326–36. https://doi.org/10.1634/theoncologist.2015-0519.CrossRefPubMedPubMedCentral

96.

Janssen L, Hopman MTE, Swaans GJA, et al. Impact of tyrosine kinase inhibitors on glucose control and insulin regulation in patients with chronic myeloid leukemia. Am J Physiol Endocrinol Metab. 2023;324(3):E209–16. https://doi.org/10.1152/ajpendo.00163.2022.CrossRefPubMed

97.

Shyam Sunder S, Sharma UC, Pokharel S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct Target Ther. 2023;8(1):262. https://doi.org/10.1038/s41392-023-01469-6.CrossRefPubMedPubMedCentral

98.

Villadolid J, Ersek JL, Fong MK, Sirianno L, Story ES. Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance. Transl Lung Cancer Res. 2015;4(5):576–83. https://doi.org/10.3978/j.issn.2218-6751.2015.10.01.CrossRefPubMedPubMedCentral

99.

Sarker D, Ang JE, Baird R, et al. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2015;21:77–86.CrossRefPubMed

100.

Shapiro GI, Rodon J, Bedell C, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2014;20:233–45.CrossRefPubMed

101.

Spencer A, Yoon SS, Harrison SJ, et al. The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014;124:2190–5.CrossRefPubMedPubMedCentral

102.

Liu D, Weintraub MA, Garcia C, et al. Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment. Cancer Med. 2022;11(8):1796–804. https://doi.org/10.1002/cam4.4579.CrossRefPubMedPubMedCentral

103.

Mulla K, Farag S, Moore B, et al. Hyperglycaemia following immune checkpoint inhibitor therapy-Incidence, aetiology and assessment. Diabet Med. 2023;40(4):e15053. https://doi.org/10.1111/dme.15053.CrossRefPubMed

104.

Lu J, Yang J, Liang Y, Meng H, Zhao J, Zhang X. Incidence of immune checkpoint inhibitor-associated diabetes: a meta-analysis of randomized controlled studies. Front Pharmacol. 2019;6(10):1453. https://doi.org/10.3389/fphar.2019.01453.CrossRef

105.

Leiter A, Carroll E, Brooks D, et al. Characterization of hyperglycemia in patients receiving immune checkpoint inhibitors: beyond autoimmune insulin-dependent diabetes. Diabetes Res Clin Pract. 2021;172:108633. https://doi.org/10.1016/j.diabres.2020.108633.CrossRefPubMed

106.

Kotwal A, Haddox C, Block M, Kudva YC. Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. BMJ Open Diabetes Res Care. 2019;7(1):e000591. https://doi.org/10.1136/bmjdrc-2018-000591.CrossRefPubMedPubMedCentral

107.

Liao D, Liu C, Chen S, et al. Recent advances in immune checkpoint inhibitor-induced type 1 diabetes mellitus. Int Immunopharmacol. 2023;122:110414. https://doi.org/10.1016/j.intimp.2023.110414.CrossRefPubMed

108.

Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3(2):178–85. https://doi.org/10.1034/j.1600-6143.2003.00010.x.CrossRefPubMed

109.

Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant. 2004;4(4):583–95. https://doi.org/10.1046/j.1600-6143.2003.00372.x.CrossRefPubMed

110.

Rodriguez-Rodriguez AE, Porrini E, Torres A. Beta-cell dysfunction induced by tacrolimus: a way to explain type 2 diabetes? Int J Mol Sci. 2021;22(19):10311. https://doi.org/10.3390/ijms221910311.CrossRefPubMedPubMedCentral

111.

Mora PF. Post-transplantation diabetes mellitus. Am J Med Sci. 2005;329:86–94.CrossRefPubMed

112.

Munoz Pena JM, Cusi K. Posttransplant diabetes mellitus: recent developments in pharmacological management of hyperglycemia. J Clin Endocrinol Metab. 2023;109(1):e1–11. https://doi.org/10.1210/clinem/dgad395.CrossRefPubMed

113.

Petersenn S, Salgado LR, Schopohl J, et al. Long-term treatment of Cushing’s disease with pasireotide: 5-year results from an open-label extension study of a phase III trial. Endocrine. 2017;57(1):156–65. https://doi.org/10.1007/s12020-017-1316-3.CrossRefPubMedPubMedCentral

114.

Lacroix A, Gu F, Gallardo W, et al. Efficacy and safety of once-monthly pasireotide in Cushing’s disease: a 12 month clinical trial. Lancet Diabetes Endocrinol. 2018;6(1):17–26. https://doi.org/10.1016/S2213-8587(17)30326-1.CrossRefPubMed

115.

Gadelha MR, Bronstein MD, Brue T, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(11):875–84. https://doi.org/10.1016/S2213-8587(14)70169-X.CrossRefPubMed

116.

Ni K, Yang JY, Baeg K, et al. Association between somatostatin analogues and diabetes mellitus in gastroenteropancreatic neuroendocrine tumor patients: a surveillance, epidemiology, and end results-Medicare analysis of 5235 patients. Cancer Rep (Hoboken). 2021;4(5):e1387. https://doi.org/10.1002/cnr2.1387.CrossRefPubMed

117.

Haris B, Saraswathi S, Hussain K. Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemia. Ther Adv Endocrinol Metab. 2020;2(11):2042018820965068. https://doi.org/10.1177/2042018820965068.CrossRef

118.

Samson SL, Gu F, Feldt-Rasmussen U, et al. Managing pasireotide-associated hyperglycemia: a randomized, open-label, phase IV study. Pituitary. 2021;24(6):887–903. https://doi.org/10.1007/s11102-021-01161-4.CrossRefPubMedPubMedCentral

119.

Mazziotti G, Porcelli T, Bogazzi F, et al. Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. Eur J Endocrinol. 2011;164(3):341-7. https://doi.org/10.1530/EJE-10-0811.

120.

Cappellani D, Urbani C, Sardella C, et al. Diabetes mellitus induced by somatostatin analogue therapy is not permanent in acromegalic patients. Endocrinol Diabetes Metab. 2018;2(1):e00033. https://doi.org/10.1002/edm2.33.CrossRefPubMedPubMedCentral

121.

Ho KK, Jenkins AB, Furler SM, Borkman M, Chisholm DJ. Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clin Endocrinol (Oxf). 1992;36(3):271–9. https://doi.org/10.1111/j.1365-2265.1992.tb01443.x.CrossRefPubMed

122.

Keating NL, Liu PH, O’Malley AJ, Freedland SJ, Smith MR. Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol. 2014;65(4):816–24. https://doi.org/10.1016/j.eururo.2013.02.023.CrossRefPubMed

123.

Wang H, Sun X, Zhao L, Chen X, Zhao J. Androgen deprivation therapy is associated with diabetes: evidence from meta-analysis. J Diabetes Investig. 2016;7(4):629–36. https://doi.org/10.1111/jdi.12472.CrossRefPubMedPubMedCentral

124.

Navarro G, Allard C, Xu W, Mauvais-Jarvis F. The role of androgens in metabolism, obesity, and diabetes in males and females. Obesity (Silver Spring). 2015;23(4):713–9. https://doi.org/10.1002/oby.21033.CrossRefPubMed

125.

Dowman JK, Hopkins LJ, Reynolds GM, et al. Loss of 5alpha-reductase type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice. Endocrinology. 2013;154:4536–47.CrossRefPubMedPubMedCentral

126.

Fan W, Yanase T, Nomura M, et al. Androgen receptor null male mice develop late-onset obesity caused by decreased energy expenditure and lipolytic activity but show normal insulin sensitivity with high adiponectin secretion. Diabetes. 2005;54:1000–8.CrossRefPubMed

127.

Zornitzki T, Malnick S, Lysyy L, Knobler H. Interferon therapy in hepatitis C leading to chronic type 1 diabetes. World J Gastroenterol. 2015;21(1):233–9. https://doi.org/10.3748/wjg.v21.i1.233.CrossRefPubMedPubMedCentral

128.

Yamazaki M, Sato A, Takeda T, Komatsu M. Distinct clinical courses in type 1 diabetes mellitus induced by peg-interferon-alpha treatment for chronic hepatitis C. Intern Med. 2010;49(5):403–7. https://doi.org/10.2169/internalmedicine.49.2656.CrossRefPubMed

129.

Biondi B, Kahaly GJ, Robertson RP. Thyroid dysfunction and diabetes mellitus: two closely associated disorders. Endocr Rev. 2019;40(3):789–824. https://doi.org/10.1210/er.2018-00163.CrossRefPubMedPubMedCentral

130.

Hage M, Zantout MS, Azar ST. Thyroid disorders and diabetes mellitus. J Thyroid Res. 2011. https://doi.org/10.4061/2011/439463.CrossRefPubMedPubMedCentral

131.

Kalra S, Aggarwal S, Khandelwal D. Thyroid dysfunction and type 2 diabetes mellitus: screening strategies and implications for management. Diabetes Ther. 2019;10(6):2035–44. https://doi.org/10.1007/s13300-019-00700-4.CrossRefPubMedPubMedCentral

132.

Altszuler N, Moraru E, Hampshire J. On the mechanism of diazoxide-induced hyperglycemia. Diabetes. 1977;26(10):931–5. https://doi.org/10.2337/diab.26.10.931.CrossRefPubMed

133.

al-Rubeaan K, Ryan EA. Phenytoin-induced insulin insensitivity. Diabet Med. 1991;8(10):968–70. https://doi.org/10.1111/j.1464-5491.1991.tb01539.x.CrossRefPubMed

134.

Carter BL, Small RE, Mandel MD, Starkman MT. Phenytoin-induced hyperglycemia. Am J Hosp Pharm. 1981;38(10):1508–12.PubMed

135.

Kahaly GJ, Douglas RS, Holt RJ, Sile S, Smith TJ. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol. 2021;9(6):360–72. https://doi.org/10.1016/S2213-8587(21)00056-5.CrossRefPubMed

136.

Shah K, Charitou M. A novel case of hyperglycemic hyperosmolar state after the use of teprotumumab in a patient with thyroid eye disease. AACE Clin Case Rep. 2022;8(4):148–9. https://doi.org/10.1016/j.aace.2022.01.004.CrossRefPubMedPubMedCentral

137.

Amarikwa L, Mohamed A, Kim SH, Kossler AL, Dosiou C. Teprotumumab-related hyperglycemia. J Clin Endocrinol Metab. 2023;108(4):858–64. https://doi.org/10.1210/clinem/dgac627.CrossRefPubMed

138.

Shen S, Chen Y, Carpio A, Chang C, Iyengar NM. Incidence, risk factors, and management of alpelisib-associated hyperglycemia in metastatic breast cancer. Cancer. 2023;129(24):3854–61. https://doi.org/10.1002/cncr.34928.CrossRefPubMed

139.

Rugo HS, André F, Yamashita T, et al. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol. 2020;31(8):1001–10. https://doi.org/10.1016/j.annonc.2020.05.001.CrossRefPubMed

140.

Kurzrock R, Patnaik A, Aisner J, et al. A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res. 2010;16(8):2458–65. https://doi.org/10.1158/1078-0432.CCR-09-3220.CrossRefPubMed

141.

Pappo AS, Patel SR, Crowley J, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol. 2011;29(34):4541–7. https://doi.org/10.1200/JCO.2010.34.0000.CrossRefPubMedPubMedCentral

142.

Burris HA, Siu LL, Infante JR, et al. Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study. J Clin Oncol. 2011;29:3003.CrossRef

143.

Coleman N, Moyers JT, Harbery A, Vivanco I, Yap TA. Clinical development of AKT inhibitors and associated predictive biomarkers to guide patient treatment in cancer medicine. Pharmgenomics Pers Med. 2021;25(14):1517–35. https://doi.org/10.2147/PGPM.S305068.CrossRef

144.

Tolcher AW, Kurzrock R, Valero V, et al. Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. Cancer Chemother Pharmacol. 2020;85(4):673–83. https://doi.org/10.1007/s00280-020-04038-8.CrossRefPubMed

145.

Yap TA, Yan L, Patnaik A, et al. Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers. Clin Cancer Res. 2014;20(22):5672–85. https://doi.org/10.1158/1078-0432.CCR-14-0868.CrossRefPubMedPubMedCentral

146.

Ramanathan RK, McDonough SL, Kennecke HF, et al. Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: a SWOG cooperative group trial (S1005). Cancer. 2015;121(13):2193–7. https://doi.org/10.1002/cncr.29363.CrossRefPubMed

147.

Bendell JC, Kurkjian C, Infante JR, et al. A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors. Invest New Drugs. 2015;33(2):463–71. https://doi.org/10.1007/s10637-015-0218-6.CrossRefPubMed

148.

Pongas G, Fojo T. BEZ235: when promising science meets clinical reality. Oncologist. 2016;21(9):1033–4. https://doi.org/10.1634/theoncologist.2016-0243.CrossRefPubMedPubMedCentral

149.

Makker V, Recio FO, Ma L, et al. A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study). Cancer. 2016;122(22):3519–28. https://doi.org/10.1002/cncr.30286.CrossRefPubMed

150.

Dolly SO, Wagner AJ, Bendell JC, et al. Phase I study of apitolisib (GDC-0980), dual phosphatidylinositol-3-kinase and mammalian target of rapamycin kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2016;22(12):2874–84. https://doi.org/10.1158/1078-0432.CCR-15-2225.CrossRefPubMedPubMedCentral

151.

Britten CD, Adjei AA, Millham R, et al. Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer. Invest New Drugs. 2014;32(3):510–7. https://doi.org/10.1007/s10637-013-0062-5.CrossRefPubMed

152.

Shapiro GI, Bell-McGuinn KM, Molina JR, et al. First-in-human study of PF-05212384 (PKI-587), a small-molecule, intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer. Clin Cancer Res. 2015;21(8):1888–95. https://doi.org/10.1158/1078-0432.CCR-14-1306.CrossRefPubMedPubMedCentral

153.

Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015;100(8):2849–52. https://doi.org/10.1210/jc.2015-1884.CrossRefPubMedPubMedCentral

Title: Medication-Induced Hyperglycemia and Diabetes Mellitus: A Review of Current Literature and Practical Management Strategies
Authors: Akshay B. Jain
Valerie Lai
Publication date: 31-07-2024
Publisher: Springer Healthcare
Keywords: Hyperglycemia
Diabetes
Medical Side Effect
Diabetes Therapy
Diabetes-associated Diseases
Diabetes Mellitus in General Practice
Lifestyle Modification for Diabetes
Metabolic Disease and Nutrition
Metabolic Diseases in General Practice
Published in: Diabetes Therapy / Issue 9/2024
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI: https://doi.org/10.1007/s13300-024-01628-0

EASD 2024

Springer Medicine

Medication-Induced Hyperglycemia and Diabetes Mellitus: A Review of Current Literature and Practical Management Strategies

Most read journal articles

Stay up to date with medical journals in your specialty

Looking for something specific?

About journals on Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2024

Tirzepatide: A Double Agonist for Various People Living with Type 2 Diabetes

PIONEER REAL Sweden: A Multicentre, Prospective, Real-World Observational Study of Oral Semaglutide Use in Adults with Type 2 Diabetes in Swedish Clinical Practice

Tirzepatide Improved Health-Related Quality of Life Compared with Insulin Lispro in Basal Insulin-Treated Adults with Type 2 Diabetes and Inadequate Glycaemic Control: A Randomised Controlled Phase 3b Trial (SURPASS-6)

Effect of Replacing Sucrose in Beverages with Nonnutritive Sweetener Sucralose on Cardiometabolic Risk Factors Among Asian Indian Adults with Type 2 Diabetes: A 12-Week Randomized Controlled Trial

Efficacy and Safety of Escalating the Dose of Oral Semaglutide from 7 to 14 mg: A Single-Center, Retrospective Observational Study

Suitability and Usefulness of a Flexible Dosing Timing of Oral Semaglutide to Maximize Benefit in Clinical Practice: An Expert Panel